PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Open Orphan plc

16 Dec 2019 14:02

RNS Number : 0225X
J & E Davy
16 December 2019
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

J&E Davy

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Open Orphan plc, the OFFEROR

(d) Is the discloser the offeror or the offeree?

(e) Date position held:

The latest practicable date prior to the disclosure

6 December 2019

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes, the OFFEREE

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Open Orphan plc ORD GBP0.001

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

1,162,237

0.46

(2) Cash-settled derivatives:

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

TOTAL:

1,162,237

0.46

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

16/12/2019

Contact name:

Matthew Donnelly

Telephone number:

+353 1 614 8720

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEGGGRAPUPBGWQ
Date   Source Headline
17th Feb 202212:05 pmRNSPositive results from RSV Human Challenge Study
14th Feb 20227:00 amRNSLaunch of STRiVE project
2nd Feb 20227:00 amRNSWorld’s first COVID-19 Characterisation Study
26th Jan 20224:40 pmRNSSecond Price Monitoring Extn
26th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSMalaria Human Challenge Model Launched
21st Dec 20217:00 amRNS£5m Influenza human challenge study contract win
16th Dec 20214:41 pmRNSSecond Price Monitoring Extn
16th Dec 20214:35 pmRNSPrice Monitoring Extension
10th Dec 202111:05 amRNSSecond Price Monitoring Extn
10th Dec 202111:00 amRNSPrice Monitoring Extension
10th Dec 20217:05 amRNSExercise of Options
10th Dec 20217:00 amRNS$13.4m Influenza HCS contract win
6th Dec 20217:00 amRNSPositive results from Flu Human Challenge Study
19th Nov 20217:00 amRNSImutex Vaccine Phase I Study Results
17th Nov 20217:00 amRNS£5.1m RSV contract
15th Nov 20217:00 amRNS£1.5m Contract renewal for Venn Life Sciences
13th Oct 20217:00 amRNSDirectorate Change
20th Sep 20217:00 amRNSHalf-year Report
20th Sep 20217:00 amRNS£5.7m Influenza human challenge study contract win
9th Sep 20217:00 amRNSNotice of Results
7th Sep 20217:00 amRNSPositive results from RSV Human Challenge Study
24th Aug 20219:05 amRNSSecond Price Monitoring Extn
24th Aug 20219:00 amRNSPrice Monitoring Extension
24th Aug 20217:00 amRNS£8.1m Asthma Human Challenge Study Contract Win
9th Aug 20217:00 amRNSMalaria Human Challenge Model
29th Jul 20217:00 amRNSDNDi Phase II trial support
22nd Jul 20217:00 amRNSNEJM Opinion Piece
21st Jul 202112:58 pmRNSResult of AGM
14th Jul 20219:06 amRNSDirectors’ Dealings
14th Jul 20218:04 amRNSAIM Schedule 1 update by Poolbeg Pharma plc
14th Jul 20217:01 amRNSNew Contract win for Open Orphan’s Breda office
14th Jul 20217:00 amRNSCOVID-19 Human Challenge Programme update
9th Jul 20217:00 amRNSHRV and Flu contract
7th Jul 20214:41 pmRNSSecond Price Monitoring Extn
7th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jun 20217:00 amRNS2020 Annual Report and 2021 AGM Notice
17th Jun 20217:00 amRNSFinal Results to 31 December 2020
17th Jun 20217:00 amRNSDemerger Update
14th Jun 20217:00 amRNSRe. Distribution in Specie and Notice of Results
11th Jun 20217:00 amRNSExercise of Warrants
19th May 20217:00 amRNSCourt Approval
10th May 20217:15 amRNSExercise of Share Options
10th May 20217:00 amRNS£3m COVID challenge virus manufacturing contract
29th Apr 202111:39 amRNSResult of General Meeting
13th Apr 20217:00 amRNSPotential demerger of certain non-core assets
9th Apr 20217:00 amRNSLaunch of Disease in Motion platform
31st Mar 20217:00 amRNSHolding(s) in Company
26th Mar 20217:00 amRNS£7.5m Human Challenge Study Contract
25th Mar 20217:00 amRNSCOVID-19 Human Challenge Programme update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.